EmblemHealth Files Class Action Antitrust Against Alexion Related to Eculizumab
By EsqSocial Corporation 01/05/25
On April 16, 2025, EmblemHealth, Inc. (“Emblem”) filed a class action suit in the District Court for the District of Massachusetts against Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Ltd. (collectively, “Alexion”) alleging Alexion “violated antitrust law by monopolistic acts that unlawfully delayed the introduction of biosimilar competition for eculizumab.”...
By: Goodwin